Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 394M |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
9 |
| Average PDX Generation Time (days +/- SEM) | 96 ± 11 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 394M |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 394M | AR | 2.564 | 5.913 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CHD7 | 1.348 | 5.091 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CHD7 | 1.210 | 4.627 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CHD7 | 1.177 | 4.523 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | AR | 2.130 | 4.377 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | PIK3CA | 1.129 | 4.375 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | KMT2A | 0.891 | 3.708 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | PIK3CB | 0.847 | 3.597 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | MRE11A | 0.646 | 3.129 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | STAB2 | 0.580 | 2.990 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | USP28 | 0.507 | 2.842 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | MET | 0.499 | 2.826 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | USP7 | -0.742 | 1.195 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | FANCA | -0.760 | 1.181 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | PTEN | -0.794 | 1.154 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | SUFU | -0.794 | 1.154 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | PRPF8 | -0.798 | 1.150 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | TP53 | -0.798 | 1.150 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CDH1 | -0.808 | 1.143 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CDKN1B | -0.852 | 1.108 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | PALB2 | -0.863 | 1.100 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | RB1 | -1.359 | 0.780 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | PTEN | -6.124 | 0.029 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CHD1 | -9.117 | 0.004 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 394M | CHD1 | -21.726 | 5.770e-07 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 394M |
|---|---|
| Sample Site | Liver |
| Sample source | Biopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, enzalutamide, navelbine |
Patient Information
| Patient Number | 394 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | NA |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 394M |
| Patient Age (binned in 5 year age groups) | 75-79 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 394M | TP53 | 206 | 1.0 | Missense variant | '7/11 | 0 | 28.8 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 394M | CDKN1B | 195 | 0.92 | Frameshift variant | '1/3 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 394M | GRIN2A | 273 | 0.45 | Missense variant | '4/14 | . | 26.1 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 394M | SPOP | 503 | 0.42 | Inframe deletion | '7/12 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table